Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses
Open accessThe DOI matches its Crossref record; 101 of the 103 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. METHODS AND FINDINGS: Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. The primary endpoints were cardiovascular mortality, myocardial infarction, and stroke-singly and as a composite endpoint, major cardiovascular outcome-and end-stage renal disease [ESRD], doubling of serum creatinine, and all-cause mortality-singly and as a composite endpoint, progression of renal disease. Secondary endpoints were angina pectoris and hospitalization for heart failure. In all, 71 trials (103,120 participants), with a total of 14 different regimens, were pooled using network meta-analyses. When compared with ACE inhibitor, no other RAS blocker used in monotherapy and/or combination was associated with a significant reduction in major cardiovascular outcomes: ARB (odds ratio [OR] 1.02; 95% credible interval [CrI] 0.90-1.18), ACE inhibitor plus ARB (0.97; 95% CrI 0.79-1.19), DR inhibitor plus ACE inhibitor (1.32; 95% CrI 0.96-1.81), and DR inhibitor plus ARB (1.00; 95% CrI 0.73-1.38). For the risk of progression of renal disease, no significant differences were detected between ACE inhibitor and each of the remaining therapies: ARB (OR 1.10; 95% CrI 0.90-1.40), ACE inhibitor plus ARB (0.97; 95% CrI 0.72-1.29), DR inhibitor plus ACE inhibitor (0.99; 95% CrI 0.65-1.57), and DR inhibitor plus ARB (1.18; 95% CrI 0.78-1.84). No significant differences were showed between ACE inhibitors and ARBs with respect to all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, angina pectoris, hospitalization for heart failure, ESRD, or doubling serum creatinine. Findings were limited by the clinical and methodological heterogeneity of the included studies. Potential inconsistency was identified in network meta-analyses of stroke and angina pectoris, limiting the conclusiveness of findings for these single endpoints. CONCLUSIONS: In adults with diabetes, comparisons of different RAS blockers showed similar effects of ACE inhibitors and ARBs on major cardiovascular and renal outcomes. Compared with monotherapies, the combination of an ACE inhibitor and an ARB failed to provide significant benefits on major outcomes. Clinicians should discuss the balance between benefits, costs, and potential harms with individual diabetes patients before starting treatment. REVIEW REGISTRATION: PROSPERO CRD42014014404.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ACE inhibitors/ARBs reduce the progression of kidney disease in patients with albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g)5 and reduce the risk of both incident and recurrent atherosclerotic ischemic events.79,80”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial treatment for hypertension should include any of the drug classes demonstrated to reduce cardiovascular events in people with diabetes (25): ACE inhibitors (67,68), ARBs (67,68), thiazide-like diuretics (69), or dihydropyridine calcium channel blockers (70).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [67]
Experimental — accuracy not yet measuredIn the citing paper
“Initial treatment for hypertension should include any of the drug classes demonstrated to reduce cardiovascular events in people with diabetes: ACE inhibitors (60,61), ARBs (60,61), thiazide-like diuretics (62), or dihydropyridine calcium channel blockers (63).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 3×
“Our review was prospectively registered in PROSPERO and also adheres to the recently developed PRISMA reporting standards for network meta-analyses (S1 Checklist) [44].”
MethodMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Inference from iterative simulation using multiple sequences
Gelman, A., & Rubin, D. B. (1992) · Statistical Science · doi:10.1214/ss/1177011136 · Cited by 16,627 · cited 1×
“We assessed convergence on the basis of Brooks–Gelman–Rubin plots [71].”
MethodVos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285 · cited 1×
“the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology [61,62] to evaluate the quality of evidence for each outcome (high, moderate, low, or very low quality).”
MethodHutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 3×
“Our review was prospectively registered in PROSPERO and also adheres to the recently developed PRISMA reporting standards for network meta-analyses (S1 Checklist) [44].”
MethodSelf-citationJames, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 1×
“Six drug manufacturers (Boehringer Ingelheim for ONTARGET [Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial] [40,41], PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes] [47], and TRANSCEND [Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiov…”
BackgroundThe combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873 · cited 1×
“Six drug manufacturers (Boehringer Ingelheim for ONTARGET [Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial] [40,41], PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes] [47], and TRANSCEND [Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiov…”
BackgroundJulius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16451-9 · Cited by 2,558
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471 · cited 2×
“In 2003, results of the Valsartan in Acute Myocardial Infarction Trial (VALIANT) [39] found no significant differences between an ARB and an ACE inhibitor in all-cause mortality or major cardiovascular events among patients with myocardial infarction complicated by congestive heart failure and/or evidence of left vent…”
BackgroundResult(2000) · PubMed · Cited by 2,095
Murray, C. J. L., Barber, R. M., Foreman, K. J., Ozgoren, A. A., Abd-Allah, F., Abera, S. F., Aboyans, V., Abraham, J. P., Abubakar, I., Abu-Raddad, L. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61340-x · Cited by 1,964
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Puhan, M. A., Schunemann, H. J., Murad, M. H., Li, T., Brignardello-Petersen, R., Singh, J. A., Kessels, A. G., Guyatt, G. H., & for the GRADE Working Group (2014) · BMJ · doi:10.1136/bmj.g5630 · Cited by 1,812 · cited 1×
“the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology [61,62] to evaluate the quality of evidence for each outcome (high, moderate, low, or very low quality).”
MethodMann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589 · cited 3×
“decades, the composite endpoints of major cardiovascular outcome and progression of renal disease have become standard outcomes of large randomized trials [13,40,41,75].”
BackgroundResultLindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319 · cited 3×
“The Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE) [22] trial was stopped prematurely because the addition of the DR inhibitor aliskiren to standard therapy with RAS blockade did not result in a decrease of cardiovascular and renal events and increased the risk of advers…”
BackgroundMethodDias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207 · cited 1×
“We used random effects network meta-analysis models as recommended elsewhere, which account for correlations in multi-arm trials [70] and which use vague (noninformative) prior distributions for all treatment effects as well as the between-study variance parameter (S3 Text).”
MethodThe Agency for Healthcare Research and Quality
Baine, W. B. (2006) · Italian Journal of Public Health · doi:10.2427/5924 · Cited by 1,191
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169 · cited 2×
“decades, the composite endpoints of major cardiovascular outcome and progression of renal disease have become standard outcomes of large randomized trials [13,40,41,75].”
BackgroundEstacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381003 · Cited by 1,166
Psaty, B. M., Lumley, T., Furberg, C. D., Schellenbaum, G., Pahor, M., Alderman, M. H., & Weiss, N. S. (2003) · JAMA · doi:10.1001/jama.289.19.2534 · Cited by 1,088
Conceptual and technical challenges in network meta-analysis
Cipriani, A., Higgins, J. P. T., Geddes, J. R., & Salanti, G. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00008 · Cited by 1,072
Tatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 850
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007994 · Cited by 792 · cited 2×
“For example, results of the Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial [50] and the Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial (ORIENT) [80] showed an increased number of cardiovascular deaths among diabetic patients randomized to the sing…”
BackgroundResultTelmisartan to Prevent Recurrent Stroke and Cardiovascular Events
Yusuf, S., Diener, H.-C., Sacco, R. L., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804593 · Cited by 785 · cited 1×
“Six drug manufacturers (Boehringer Ingelheim for ONTARGET [Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial] [40,41], PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes] [47], and TRANSCEND [Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiov…”
BackgroundCasas, J. P., Chua, W., Loukogeorgakis, S., Vallance, P., Smeeth, L., Hingorani, A. D., & MacAllister, R. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67814-2 · Cited by 745
Dias, S., Welton, N. J., Sutton, A. J., Caldwell, D. M., Lu, G., & Ades, A. E. (2013) · Medical Decision Making · doi:10.1177/0272989x12455847 · Cited by 728
Ioannidis, J. P. A. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081086 · Cited by 716
Daskalopoulou, S. S., Rabi, D. M., Zarnke, K. B., Dasgupta, K., Nerenberg, K., Cloutier, L., Gelfer, M., Lamarre-Cliche, M., Milot, A., Bolli, P., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.02.016 · Cited by 684
Ferreira-González, I., Permanyer-Miralda, G., Domingo-Salvany, A., Busse, J. W., Heels-Ansdell, D., Montori, V. M., Akl, E. A., Bryant, D. M., Alonso-Coello, P., Alonso, J., et al. (2007) · BMJ · doi:10.1136/bmj.39136.682083.ae · Cited by 473
Dias, S., Sutton, A. J., Welton, N. J., & Ades, A. E. (2013) · Medical Decision Making · doi:10.1177/0272989x13485157 · Cited by 466 · cited 1×
“Other preplanned analyses were the extension of the primary unadjusted network meta-analysis model to include covariates in meta-regression models [74] that considered adjustments for the following: year of publication, mean age of trial participants, percent of male participants, and control group risk rate.”
Methodvan Vark, L. C., Bertrand, M., Akkerhuis, K. M., Brugts, J. J., Fox, K., Mourad, J.-J., & Boersma, E. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs075 · Cited by 460
Chaturvedi, N., Porta, M., Klein, R., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Sjølie, A. K. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61412-9 · Cited by 451 · cited 1×
“Six drug manufacturers (Boehringer Ingelheim for ONTARGET [Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial] [40,41], PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes] [47], and TRANSCEND [Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiov…”
BackgroundValidity of composite end points in clinical trials
Montori, V. M., Permanyer-Miralda, G., Ferreira-González, I., Busse, J. W., Pacheco-Huergo, V., Bryant, D., Alonso, J., Akl, E. A., Domingo-Salvany, A., Mills, E., et al. (2005) · BMJ · doi:10.1136/bmj.330.7491.594 · Cited by 442 · cited 1×
“However, it is acknowledged that the use of composite endpoints is frequently complicated because of poor reporting and uncertain clinical relevance in many trials [86,87].”
BackgroundSjølie, A. K., Klein, R., Porta, M., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Chaturvedi, N. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61411-7 · Cited by 435
Palmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62459-4 · Cited by 395
Strippoli, G. F. M., Craig, M., Deeks, J. J., Schena, F. P., & Craig, J. C. (2004) · BMJ · doi:10.1136/bmj.38237.585000.7c · Cited by 385
Gheorghiade, M., Böhm, M., Greene, S. J., Fonarow, G. C., Lewis, E. F., Zannad, F., Solomon, S. D., Baschiera, F., Botha, J., Hua, T. A., et al. (2013) · JAMA · doi:10.1001/jama.2013.1954 · Cited by 328 · cited 5×
“Similarly, the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) [56] failed to show that the DR inhibitor was superior to placebo in addition to standard therapy in reducing cardiovascular death or heart failure rehospitalization among patients hospitalized for heart failure with reduced left ventricular ej…”
BackgroundMethodResultInfluentialFluid Resuscitation in Sepsis: A Systematic Review and Network Meta-analysis
Rochwerg, B., Alhazzani, W., Sindi, A., Heels-Ansdell, D., Thabane, L., Fox-Robichaud, A., Mbuagbaw, L., Szczeklik, W., Alshamsi, F., Altayyar, S., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0178 · Cited by 309
Agency for Healthcare Research and Quality: EXTRAMURAL SUPPORT FOR REHABILITATION ACTIVITIES
Reynolds, P. (2005) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/01.phm.0000189844.24790.9f · Cited by 291
Whelton, P. K. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1401 · Cited by 290 · cited 1×
“Six drug manufacturers (Boehringer Ingelheim for ONTARGET [Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial] [40,41], PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes] [47], and TRANSCEND [Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiov…”
BackgroundCheng, J., Zhang, W., Zhang, X., Han, F., Li, X., He, X., Li, Q., & Chen, J. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.348 · Cited by 280
Dasgupta, K., Quinn, R. R., Zarnke, K. B., Rabi, D. M., Ravani, P., Daskalopoulou, S. S., Rabkin, S. W., Trudeau, L., Feldman, R. D., Cloutier, L., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.02.002 · Cited by 270
Bilous, R., Chaturvedi, N., Sjølie, A. K., Fuller, J., Klein, R., Orchard, T., Porta, M., & Parving, H.-H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-1-200907070-00120 · Cited by 252 · cited 1×
“Six drug manufacturers (Boehringer Ingelheim for ONTARGET [Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial] [40,41], PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes] [47], and TRANSCEND [Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiov…”
BackgroundStrauss, M. H., & Hall, A. S. (2006) · Circulation · doi:10.1161/circulationaha.105.594986 · Cited by 249
Makani, H., Bangalore, S., Desouza, K. A., Shah, A., & Messerli, F. H. (2013) · BMJ · doi:10.1136/bmj.f360 · Cited by 244
for the ORIENT study investigators, Imai, E., Chan, J. C. N., Ito, S., Yamasaki, T., Kobayashi, F., Haneda, M., & Makino, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2325-z · Cited by 236 · cited 1×
“For example, results of the Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial [50] and the Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial (ORIENT) [80] showed an increased number of cardiovascular deaths among diabetic patients randomized to the sing…”
ResultWu, H.-Y., Huang, J.-W., Lin, H.-J., Liao, W.-C., Peng, Y.-S., Hung, K.-Y., Wu, K.-D., Tu, Y.-K., & Chien, K.-L. (2013) · BMJ · doi:10.1136/bmj.f6008 · Cited by 233
Niskanen, L., Hedner, T., Hansson, L., Lanke, J., Niklason, A., & for the CAPPP study group (2001) · Diabetes Care · doi:10.2337/diacare.24.12.2091 · Cited by 219
Angiotensin receptor blockers and myocardial infarction
Verma, S., & Strauss, M. (2004) · BMJ · doi:10.1136/bmj.329.7477.1248 · Cited by 210
Lindholm, L. H., Hansson, L., Ekbom, T., Dahlöf, B., Lanke, J., Linjer, E., Scherstéln, B., Wester, P. O., Hedner, T., & de Faire, U. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018110-00020 · Cited by 198
Effect of Telmisartan on Renal Outcomes: A Randomized Trial
Mann, J. F. E., Schmieder, R. E., Dyal, L., McQueen, M. J., Schumacher, H., Pogue, J., Wang, X., Probstfield, J. L., Avezum, A., Cardona-Munoz, E., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-1-200907070-00122 · Cited by 196
Savarese, G., Costanzo, P., Cleland, J. G. F., Vassallo, E., Ruggiero, D., Rosano, G., & Perrone-Filardi, P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.011 · Cited by 193
Self-citationSciarretta, S., Palano, F., Tocci, G., Baldini, R., & Volpe, M. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.427 · Cited by 185
Network meta-analysis for comparing treatment effects of multiple interventions: an introduction
Catalá-López, F., Tobías, A., Cameron, C., Moher, D., & Hutton, B. (2014) · Rheumatology International · doi:10.1007/s00296-014-2994-2 · Cited by 170 · cited 1×
“Network meta-analysis [67,68] allows the integration of data from both direct and indirect evidence, increasing precision while randomization is preserved, but can also be used to estimate comparisons between pairs of treatments that have not been compared in individual studies.”
BackgroundSelf-citationClarke, P. M., Glasziou, P., Patel, A., Chalmers, J., Woodward, M., Harrap, S. B., Salomon, J. A., & on behalf of the ADVANCE Collaborative Group (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000236 · Cited by 159
Vejakama, P., Thakkinstian, A., Lertrattananon, D., Ingsathit, A., Ngarmukos, C., & Attia, J. (2012) · Diabetologia · doi:10.1007/s00125-011-2398-8 · Cited by 152
Bangalore, S., Kumar, S., Wetterslev, J., & Messerli, F. H. (2011) · BMJ · doi:10.1136/bmj.d2234 · Cited by 137
Daly, C. A., Fox, K. M., Remme, W. J., Bertrand, M. E., Ferrari, R., & Simoons, M. L. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi225 · Cited by 133
Krum, H., Massie, B., Abraham, W. T., Dickstein, K., Kober, L., McMurray, J. J. V., Desai, A., Gimpelewicz, C., Kandra, A., Reimund, B., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq212 · Cited by 127 · cited 1×
“As a consequence of these findings, regulatory authorities recommended new contraindications and warnings for aliskiren-containing medicines in patients with diabetes or kidney problems [83] and required aliskiren investigational treatment to be withdrawn from patients with diabetes in Aliskiren Trial to Minimize Outc…”
BackgroundSavarese, G., Costanzo, P., Cleland, J. G. F., Vassallo, E., Ruggiero, D., Rosano, G., & Perrone-Filardi, P. (2013) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2013-9-2-188-200 · Cited by 104
Self-citationBaker, W. L., Coleman, C. I., Kluger, J., Reinhart, K. M., Talati, R., Quercia, R., Phung, O. J., & White, C. M. (2009) · PubMed · doi:10.7326/0003-4819-151-12-200912150-00162 · Cited by 91
Surveillance search techniques identified the need to update systematic reviews
Sampson, M., Shojania, K. G., McGowan, J., Daniel, R., Rader, T., Iansavitchene, A., Ji, J., Ansari, M. T., & Moher, D. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.10.003 · Cited by 86 · cited 1×
“This technique has been shown to be effective in identifying relevant studies [45], increases efficiency in study identification in the presence of an already large evidence base, and is being used as part of an ongoing network meta-analysis research program [46].”
MethodBaker, W. L., Coleman, C. I., Kluger, J., Reinhart, K. M., Talati, R., Quercia, R., Phung, O. J., & White, C. M. (2009) · Annals of Internal Medicine · doi:10.7326/0000605-200912150-00162 · Cited by 78
Xue, H., Lu, Z., Tang, W. L., Pang, L. W., Wang, G. M., Wong, G. W., & Wright, J. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008170.pub2 · Cited by 70
Kuenzli, A., Bucher, H. C., Anand, I. S., Arutyunov, G. P., Kum, L. C. C., McKelvie, R. S., Afzal, R., White, M., & Nordmann, A. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009946 · Cited by 59
Ogihara, T., Saruta, T., Rakugi, H., Saito, I., Shimamoto, K., Matsuoka, H., Shimada, K., Ito, S., Horiuchi, M., Imaizumi, T., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000281 · Cited by 48
for the CASE-J Trial Group, Nakao, K., Hirata, M., Oba, K., Yasuno, S., Ueshima, K., Fujimoto, A., Ogihara, T., & Saruta, T. (2010) · Hypertension Research · doi:10.1038/hr.2010.38 · Cited by 41 · cited 1×
“Six drug manufacturers (Boehringer Ingelheim for ONTARGET [Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial] [40,41], PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes] [47], and TRANSCEND [Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiov…”
BackgroundNakao, Y. M., Teramukai, S., Tanaka, S., Yasuno, S., Fujimoto, A., Kasahara, M., Ueshima, K., Nakao, K., Hinotsu, S., Nakao, K., et al. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.11.025 · Cited by 24
Hutton, B., Tetzlaff, J., Yazdi, F., Thielman, J., Kanji, S., Fergusson, D. A., Bjerre, L. M., Mills, E. J., Thorlund, K., Tricco, A. C., et al. (2013) · Systematic Reviews · doi:10.1186/2046-4053-2-44 · Cited by 19 · cited 1×
“This technique has been shown to be effective in identifying relevant studies [45], increases efficiency in study identification in the presence of an already large evidence base, and is being used as part of an ongoing network meta-analysis research program [46].”
MethodSelf-citationCatalá-López, F., Hutton, B., & Moher, D. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.11.016 · Cited by 13 · cited 1×
“When performing a network meta-analysis, we relied on the assumptions of transitivity [69] (i.”
MethodSelf-citationTelmisartan prevents cardiovascular events in a broad group of at-risk patients
Baumhäkel, M., & Böhm, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903449231 · Cited by 11
Daly, C., Fox, K. M., Remme, W. J., Bertrand, M. E., Ferrari, R., & Simoons, M. L. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.10.023 · Cited by 11 · cited 1×
“Six drug manufacturers (Boehringer Ingelheim for ONTARGET [Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial] [40,41], PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes] [47], and TRANSCEND [Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiov…”
Backgroundfor the OlmeSartan Calcium Antagonists Randomized (OSCAR) Study Group, Matsui, K., Kim‐Mitsuyama, S., Ogawa, H., Jinnouchi, T., Jinnouchi, H., & Arakawa, K. (2014) · Hypertension Research · doi:10.1038/hr.2014.23 · Cited by 11 · cited 1×
“Six drug manufacturers (Boehringer Ingelheim for ONTARGET [Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial] [40,41], PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes] [47], and TRANSCEND [Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiov…”
BackgroundMore about the “ARB MI paradox”
Hall, A. S., & Strauss, M. H. (2007) · Heart · doi:10.1136/hrt.2006.107185 · Cited by 9
Diabetes, aliskiren, and heart failure: let's bring ASTRONAUT down to earth
Cleland, J. G. F., Clark, A., Costanzo, P., & Francis, D. P. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht366 · Cited by 7
Angiotensin receptor blockers and cardiovascular outcomes
Hobbs, R. F. (2011) · BMJ · doi:10.1136/bmj.d2193 · Cited by 3
Cited by
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
“Initial treatment for hypertension should include any of the drug classes demonstrated to reduce cardiovascular events in patients with diabetes: ACE inhibitors (58,59), angiotensin receptor blockers (ARBs) (58,59), thiazide-like diuretics (60), or dihydropyridine calcium channel blockers (61).”
BackgroundDiabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
“In general, ACE inhibitors and ARBs are considered to have similar benefits and risks, and if one is not tolerated, the other can often be used (65,83).”
BackgroundTreatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
Metadata
- Authors
- Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., Tabarés-Seisdedos, R., & Hutton, B.
- Affiliations
- Universitat de València (ES)
- IRCCS San Raffaele Roma (IT)
- The University of Texas Health Science Center at Houston (US)
- Agencia Española de Medicamentos y Productos Sanitarios (ES)
- University of Ottawa (CA)
- Corresponding author
- Catalá-López, Ferrán
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-03-08
- Volume
- 13
- Issue
- 3
- Pages
- e1001971
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC4783064
- OpenAlex
- W2292998606
- Cited by
- 109
- References
- 103
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 8 · 2020: 18 · 2019: 12 · 2018: 16 · 2017: 10 · 2016: 2
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-06-10)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Digital Collections of Colorado (Colorado State University) (submittedVersion)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Generalitat Valenciana (PROMETEOII/2015/021)
- Centro de Investigación Biomédica en Red de Salud Mental
- INCLIVA Instituto de Investigación Sanitaria
- Canadian Institutes of Health Research
- Instituto de Salud Carlos III (PROMETEOII/2015/021, PI14/00894, PI14/)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- renin-angiotensin system blockade, diabetes mellitus, ACE inhibitors, angiotensin receptor blockers, renin inhibitors, cardiovascular outcomes, renal outcomes, end-stage renal disease, cardiovascular mortality, myocardial infarction, stroke, heart failure hospitalization, angina pectoris, combination therapy, all-cause mortality, serum creatinine
- MeSH terms
- Renin Inhibitors, Adult, Angina Pectoris, Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Heart Failure, Hospitalization, Humans, Kidney Failure, Chronic, Myocardial Infarction, Renin-Angiotensin System, Stroke, Diabetes Complications, Renal Insufficiency, Chronic, Secondary Prevention, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.